Through the use of a multimodal system, Viz Assist provides generative AI summaries of patient histories that may ehance care coordination and facilitate more timely interventions.

Pluvicto in combination with the standard of care led to a 28 percent reduction in the risk of radiographic progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results from the phase III PSMAddition trial presented at the European Society for Medical Oncology (ESMO) conference.

Seemingly over the top efforts for recredentialing of radiologists may have an adverse impact on a facility’s retention and recruitment.

Catch up on the top radiology content of the past week.

The iron-based brain MRI contrast agent Ferabright (ferumoxytol injection) is indicated for adult patients with known or suspected malignant neoplasms.

Concordant mammography detection of breast cancer by radiologists and AI had over a threefold higher likelihood of future incidental breast cancer in comparison to positive radiologist assessment and negative AI evaluation, according to new research involving over 82,000 women.

The AI-enabled LungQ® 4 software reportedly offers enhanced segmentation of peripheral airways and estimates of chronic perfusion deficits based on analysis of chest CT scans.

Facilitating timely detection and follow-up management of patients with aortic aneurysms, the PRAEVAorta2 software reportedly enables automated measurement of aortic diameters on computed tomography (CT) scans.

While a new meta-analysis of the PI-RADS v2.1 criteria showed 96 percent and 88 percent sensitivity rates for PI-RADS category > 3 and PI-RADS category > 4 assessments respectively, researchers noted a high risk of bias in 29 percent of the reviewed studies.

New enhancements for the Venue POCUS devices include automated labeling of anatomical landmarks with Nerveblox to facilitate 12 common peripheral nerve blocks and contrast-enhanced ultrasound geared to abdominal injury assessments.

In the second part of a recent interview, Emmanuel S. Antonarakis, M.D. discusses PSMA PET agents in current trials and cell surface proteins that may offer targeting utility in prostate cancer imaging beyond PSMA.

In the 160-patient study comparing 18F-PSMA 1007 PET/CT and 18F-NaF PET/CT, the use of 18F-PSMA PET/CT led to 38 patients being restaged as having more advanced prostate cancer.

Through enhanced data interoperability and access to patient histories, the cloud-based InteleHeart may facilitate better communication and workflow efficiencies for radiologists and cardiologists.

While dynamic contrast enhanced breast MRI may help reduce biopsies for suspicious calcifications on mammograms, quantitative MRI features and diffusion-weighted imaging (DWI) may not provide additional diagnostic benefit in these cases, according to a new study.

A deep learning AI platform, which incorporated radiomic features including CT attenuation metrics, demonstrated a 93.6 percent AUC for detecting invasive adenocarcinoma on chest CT.